Antipsychotic Agents - Pharmacology
Research News and Information

Monday, November 23, 2009

Asenapine.

30 Oct 2009 In August 2009, asenapine (Saphris; Schering-Plough) was approved by the US FDA for the acute treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in ... Read more...

The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia.

29 Sep 2009 Olanzapine is a second-generation antipsychotic that may cause weight gain and metabolic syndrome in some cases. The peroxisome proliferator-activated receptor (PPAR)-gamma is an important gene in the progress of type II diabetes and metabolic ... Read more...

Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects.

14 Sep 2009 BACKGROUND: Although much progress has been made on antipsychotic drug development, precise mechanisms behind the action of typical and atypical antipsychotics are poorly understood. METHODS: We performed genome-wide expression profiling to study ... Read more...

Latest indexed articles for 'Antipsychotic Agents - Pharmacology'

These are the very latest articles for this heading:

• Asenapine. 30 Oct 2009
• The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia. 29 Sep 2009
• Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects. 14 Sep 2009
• Asenapine. 30 Aug 2009
• Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. 30 Aug 2009
• Motor circuit abnormalities in first-episode schizophrenia assessed with transcranial magnetic stimulation. 30 Aug 2009
• Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. 30 Aug 2009
• Impact of antipsychotic treatments on the motivation to eat: preliminary results in 153 schizophrenic patients. 30 Aug 2009
• [Neurobiological and pharmacologic aspects of atypical antipsychotic drugs] 14 Aug 2009
• Longer-term treatment of patients with bipolar disorder: a 9-month observational study in Central and Eastern Europe, the Middle East and Africa. 30 Jul 2009
• Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. 30 Jul 2009
• Effect of risperidone on emotion recognition deficits in antipsychotic-naïve schizophrenia: a short-term follow-up study. 30 Jul 2009
• Abnormal transbilayer distribution of phospholipids in red blood cell membranes in schizophrenia. 28 Jul 2009
• Clozapine, GABA(B), and the treatment of resistant schizophrenia. 20 Jul 2009
• In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia. 15 Jul 2009
• Decreased expression of NMDA receptor-associated proteins in frontal cortex of elderly patients with schizophrenia. 13 Jul 2009
• Elevated anticardiolipin antibodies in schizophrenic patients before and during neuroleptic medication. 10 Jul 2009
• Strategies to promote differentiation of newborn neurons into mature functional cells in Alzheimer brain. 7 Jul 2009
• Commentary: genome-based CNS drug discovery: D-amino acid oxidase (DAAO) as a novel target for antipsychotic medications: progress and challenges. 6 Jul 2009
• A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists. Jul 2009

See a longer list of these articles.

Technical information about 'Antipsychotic Agents'

Definition: Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in schizophrenia, senile dementia, transient psychosis following surgery or myocardial infarction, etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.

Registry Number: 0

Descriptor UI: D014150

Alternative terms: Antipsychotic Agents; Agents, Antipsychotic; Tranquilizing Agents, Major; Agents, Major Tranquilizing; Major Tranquilizing Agents; Tranquillizing Agents, Major; Agents, Major Tranquillizing; Major Tranquillizing Agents; Major Tranquilizers; Tranquilizers, Major; Antipsychotics; Antipsychotic Drugs; Drugs, Antipsychotic; Neuroleptic Drugs; Drugs, Neuroleptic; Neuroleptics; Neuroleptic Agents; Agents, Neuroleptic;

Related Mesh Headings: Dopamine Antagonists;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.696.277.950.040; D27.505.954.427.210.950.040; D27.505.954.427.700.872.331;

Online Note: use ANTIPSYCHOTIC AGENTS to search TRANQUILIZING AGENTS, MAJOR 1975-94; use TRANQUILIZING AGENTS to search NEUROLEPTICS 1969-94

History Note: 95; was TRANQUILIZING AGENTS, MAJOR 1975-94; ANTIPSYCHOTIC AGENTS was see TRANQUILIZING AGENTS, MAJOR 1975-94; NEUROLEPTICS was see TRANQUILIZING AGENTS 1975-78, was see under TRANQUILIZING AGENTS 1969-74

Technical Notes: GEN or unspecified; prefer specific groups or specific drugs; consider also PSYCHOSES /drug ther